1346 GMT - The receipt of all regulatory approvals allowing Novo Nordisk's Catalent acquisition is important and should see share price upside as it improves supply visibility, Bank of America Securities analysts Sachin Jain and Graham Parry write. The acquisition is expected to gradually increase Novo's filling capacity from 2026 onwards. However, share price upside potential may be capped given investor nerves into the imminent phase 3 trial data from obesity drug CagriSema, they say. The bank expects around 10% share price upside potential if CagriSema confirms 25% weight loss, versus 15%-20% share price upside potential if weight-loss is over 27%. Shares rise 1.8% to 767.50 Danish kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
December 16, 2024 08:46 ET (13:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。